Financings in Brief: Aastrom Biosciences
This article was originally published in The Gray Sheet
Aastrom Biosciences: Company plans a secondary offering of 1.5 mil. shares of common stock. Net proceeds will help fund clinical trials of Aastrom's cell production system, designed for use in large scale ex vivo production of a variety of therapeutic cells ("The Gray Sheet" May 26, I&W-11), as well as R&D of other product candidates, and provide working capital. Cowen & Company is managing the deal...
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”